This is a preview of subscription content, log in via an institution to check access.
Notes
Macrocyclic agents comprise gadoterate meglumine [Dotarem], gadoteridol [ProHance] and gadobutrol [Gadovist]. Linear agents comprise gadopentetate dimeglumine [Magnevist], gadobenate dimeglumine [MultiHance], gadodiamide [Omniscan], gadoversetamide [Optimark] and gadoxetate disodium [Primovist].
Reference
Health Canada. Summary Safety Review - Gadolinium based contrast agents - Assessing the risk of gadolinium build-up in the brain and potential brain and nervous system (neurological) side effects. Internet Document : 1 May 2018. Available from: URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/gadolinium-based-contrast-agents-assessing-risk-build-up-in-brain-and-potential-brain-nervous-system-side-effects.html
Rights and permissions
About this article
Cite this article
Risk of neurological events with gadolinium-based contrast agents. Reactions Weekly 1701, 5 (2018). https://doi.org/10.1007/s40278-018-45837-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-45837-8